

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

1602

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/70</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/15203</b> <b>(43) International Publication Date:</b> 23 March 2000 (23.03.00)
<b>(21) International Application Number:</b> PCT/EP99/06298 <b>(22) International Filing Date:</b> 27 August 1999 (27.08.99) <b>(30) Priority Data:</b> 9820012.4 14 September 1998 (14.09.98) GB <b>(71) Applicant (for all designated States except US):</b> PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1,2, I-20152 Milano (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PACCARINI, Maria, Adele [IT/IT]; Via degli Imbriani, 39, I-20158 Milano (IT). VALOTA, Olga [IT/IT]; Via Nazario Sauro, 99, I-20025 Legnano (IT). KERR, David [GB/GB]; 27 Westhill Road, Kings Norton, Birmingham B38 8TL (GB).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report</i> <b>(88) Date of publication of the international search report:</b> 20 July 2000 (20.07.00)	
<b>(54) Title:</b> <u>USE OF METHOXYMORPHOLINO DOXORUBICIN FOR THE TREATMENT OF A LIVER TUMOR</u>		
<b>(57) Abstract</b> <p>The present invention relates to the use of methoxymorpholino doxorubicin for the treatment of a liver cancer; in particular, it refers to the intrahepatic administration of methoxymorpholino doxorubicin for use in the liver tumor therapy optionally in association with an agent which remains selectively in liver tumor after its injection through the hepatic artery.</p>		